The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. Scientists say this ...

European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.

A key advantage of the drug is its oral route of administration, offering patients a more convenient alternative to ...

The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side effects ...

Sarepta continues to work with regulators to complete the safety label update for Elevidys, and they are discussing an approach for risk mitigation for non-ambulatory patients.

The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.

Once touted as a potential powerhouse treatment for a variety of inflammatory conditions, Galapagos’ JAK inhibitor Jyseleca ...

European Medicines Agency recognizes potential of lead compound MP1032 in addressing a high unmet medical need in Duchenne Muscular Dystrophy (DMD)Designation is paving the way for safer long-term ...

Sarepta ( SRPT) will begin shipping its top-selling muscular dystrophy therapy, Elevidys, after the U.S. Food and Drug ...

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, KalVista ...